Search

Your search keyword '"Neuburger, Stefan"' showing total 16 results
Start Over Author "Neuburger, Stefan"
16 results on '"Neuburger, Stefan"'

1. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016

Author

Ullmann, Andrew J., Schmidt-Hieber, Martin, Bertz, Hartmut, Heinz, Werner J., Kiehl, Michael, Krüger, William, Mousset, Sabine, Neuburger, Stefan, Neumann, Silke, Penack, Olaf, Silling, Gerda, Vehreschild, Jörg Janne, Einsele, Hermann, Maschmeyer, Georg, and on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)

Published
2016
Full Text
View/download PDF

2. Cidofovir for BK Virus-Associated Hemorrhagic Cystitis: A Retrospective Study

Author

Cesaro, Simone, Hirsch, Hans H., Faraci, Maura, Owoc-Lempach, Joanna, Beltrame, Angela, Tendas, Andrea, Baltadakis, Ioannis, Dalle, Jean-Hughes, Koc, Yener, Toporski, Jacek, Styczynski, Jan, Yesilipek, M. Akif, Heinz, Werner, Caniglia, Maurizio, Rascon, Jelena, Fauser, Axel A., Michallet, Mauricette, Lopez-Corral, Lucia, Neuburger, Stefan, Tridello, Gloria, and Einsele, Herman

Published
2009
Full Text
View/download PDF

5. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Author

Martino, Rodrigo, Parody, Rocio, Fukuda, Takahiro, Maertens, Johan, Theunissen, Koen, Ho, Aloysius, Mufti, Ghulam J., Kroger, Nicolaus, Zander, Arnold R., Heim, Dominik, Paluszewska, Monika, Selleslag, Dominik, Steinerova, Katerina, Ljungman, Per, Cesaro, Simone, Nihtinen, Anna, Cordonnier, Catherine, Vazquez, Lourdes, López-Duarte, Monica, Lopez, Javier, Cabrera, Rafael, Rovira, Montserrat, Neuburger, Stefan, Cornely, Oliver, Hunter, Ann E., Marr, Kieren A., Dornbusch, Hans Jürgen, and Einsele, Hermann

Published
2006
Full Text
View/download PDF

7. Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Author

Hemmati, Philipp, primary, Massenkeil, Gero, additional, Terwey, Theis, additional, Neuburger, Stefan, additional, le Coutre, Philipp D., additional, Vuong, Lam G, additional, Dörken, Bernd, additional, and Arnold, Renate, additional

Published
2008
Full Text
View/download PDF

8. Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Author

Hemmati, Philipp, primary, Terwey, Theis, additional, Massenkeil, Gero, additional, le Coutre, Philipp D., additional, Neuburger, Stefan, additional, Vuong, Lam G, additional, Dörken, Bernd, additional, and Arnold, Renate, additional

Published
2008
Full Text
View/download PDF

15. Cidofovir for BK Virus-Associated Hemorrhagic Cystitis: A Retrospective Study

Author

Cesaro, Simone, Hirsch, Hans H., Faraci, Maura, Owoc-Lempach, Joanna, Beltrame, Angela, Tendas, Andrea, Baltadakis, Ioannis, Dalle, Jean-Hughes, Koc, Yener, Toporski, Jacek, Styczynski, Jan, Yesilipek, M. Akif, Heinz, Werner, Caniglia, Maurizio, Rascon, Jelena, Fauser, Axel A., Michallet, Mauricette, Corral, Lucia Lopez, Neuburger, Stefan, Tridello, Gloria, Einsele, Herman, Cesaro, Simone, Hirsch, Hans H., Faraci, Maura, Owoc-Lempach, Joanna, Beltrame, Angela, Tendas, Andrea, Baltadakis, Ioannis, Dalle, Jean-Hughes, Koc, Yener, Toporski, Jacek, Styczynski, Jan, Yesilipek, M. Akif, Heinz, Werner, Caniglia, Maurizio, Rascon, Jelena, Fauser, Axel A., Michallet, Mauricette, Corral, Lucia Lopez, Neuburger, Stefan, Tridello, Gloria, and Einsele, Herman

Abstract

Background.BK virus-associated hemorrhagic cystitis (BKV-HC) is a severe complication after allogeneic hematopoietic stem cell transplantation (HSCT), but antiviral treatment for this condition has not been evaluated. Methods.We conducted a retrospective survey on the safety and outcome of cidofovir treatment for patients with BKV-HC in centers affiliated with the European Group for Blood and Marrow Transplantation. Results.From 1 April 2004 to 31 December 2007, 62 patients received a diagnosis of BKV-HC after a median interval of 35 days after HSCT (range, 3-577 days). Fifty-seven patients (92%) received intravenous cidofovir, whereas 5 patients received cidofovir intravesically. Complete response (CR) was recorded in 38 (67%) of 57 patients with HC treated with intravenous cidofovir, whereas partial response (PR) was documented in 7 patients (12%). CR was documented in 3 patients and PR in 1 patient with HC treated with intravesical cidofovir. A reduction of 1-3 logs in BKV load was documented in 8 of the 10 patients achieving CR. Mild-to-moderate toxic effects were recorded in 18 of 57 patients who received intravenous cidofovir administration. In a multivariate analysis, the factors significantly associated with response to cidofovir were the stem cell source (P=.01) and the use of total body irradiation (P=.03). After a median follow-up of 287 days, overall survival and total treatment-related mortality rates were 63% and 40% for patients achieving CR, compared with 14% and 72% for patients with PR or no response to cidofovir, respectively (P<.001 and P=.001, respectively). Conclusions.Cidofovir may be a potentially effective therapy for BKV-HC, but evidence supporting its use requires randomized controlled trials

16. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.

Author

Schmidt-Hieber M, Schwender J, Heinz WJ, Zabelina T, Kühl JS, Mousset S, Schüttrumpf S, Junghanss C, Silling G, Basara N, Neuburger S, Thiel E, and Blau IW

Subjects
Adolescent, Adult, Aged, Alemtuzumab, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm therapeutic use, Antineoplastic Agents therapeutic use, Antiviral Agents therapeutic use, Child, Child, Preschool, Combined Modality Therapy, Encephalitis, Viral drug therapy, Female, Hematologic Neoplasms therapy, Humans, Immunosuppressive Agents therapeutic use, Infant, Lymphocyte Depletion, Male, Middle Aged, Muromonab-CD3 therapeutic use, Retrospective Studies, Survival Rate, Transplantation, Homologous, Treatment Outcome, Virus Activation, Young Adult, Encephalitis, Viral etiology, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation adverse effects
Abstract

Background: Limited data are available on characteristics of viral encephalitis in patients after allogeneic stem cell transplantation., Design and Methods: We analyzed 2,628 patients after allogeneic stem cell transplantation to identify risk factors and characteristics of viral encephalitis., Results: Viral encephalitis occurred in 32 patients (1.2%, 95% confidence interval 0.8%-1.6%) and was associated with the use of OKT-3 or alemtuzumab for T-cell depletion (P < 0.001) and an increased mortality (P = 0.011) in comparison to patients without viral encephalitis. Detected viruses included human herpesvirus-6 (28%), Epstein-Barr virus (19%), herpes simplex virus (13%), JC virus (9%), varicella zoster virus (6%), cytomegalovirus (6%) and adenovirus (3%). More than one virus was identified in 16% of the patients. The median onset time was 106 days after allogeneic stem cell transplantation for the total group of 32 patients, but onset times were shortest in those with human herpesvirus-6 encephalitis and longest in those with JC virus-associated progressive multifocal leukoencephalopathy. The probability of a sustained response to treatment was 63% (95% confidence interval 44%-82%) with a median survival of 94 (95% confidence interval 36-152) days after onset, but significant variation was found when considering different causative viruses. Patients with herpes simplex virus encephalitis had the most favorable outcome with no encephalitis-related deaths., Conclusions: The use of OKT-3 or alemtuzumab for in vivo T-cell depletion is associated with an increased risk of viral encephalitis after allogeneic stem cell transplantation. Different viruses are frequently associated with distinct characteristics such as onset time, response to treatment and outcome.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results